DRUG
MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics
Status
Completed
Phase
Not applicable
Enrollment
57
Locations
1
Results
Posted
Publications
12
Study summary
What the protocol is testing.
The goal of this research study is to learn more about the pancreas. The investigators want to use Magnetic Resonance Cholangiopancreatography (MRCP) to learn more about the size of a normal pancreas. MRCP is a special kind of MRI exam that produces detailed images of the pancreas. The investigators also want to figure out how much fluid the pancreas releases in response to secretin. Secretin is a chemical in the body that causes the pancreas to release fluid that helps with digestion. Secretin is used during the MRCP (MR-PFT) to help identify dysfunction of the pancreas. MR elastography (MRE) will be used to measure how hard the pancreas is. MRE is a special kind of MRI that uses vibrations to image tissue.
Full detailed description
Introduction/Methods: Pancreatic fibrosis is the end stage of chronic pancreatitis (CP), which leads to loss of acinar volume and secretory capacity, and ultimately pancreatic insufficiency (PI). CP and congenital PI affect the pediatric population, and are both increasingly recognized in children. PI has serious negative implications on a child's growth and health but, if diagnosed early, PI can be treated, minimizing the detrimental effects of PI. Currently, direct pancreatic function testing (PFT) via collection of pancreatic fluid is the "gold standard" for diagnosis of PI but it is an invasive testing that may require sedation or general anesthesia. Magnetic resonance cholangiopancreatography (MRCP) with secretin administration (MR-PFT) and MR elastography (MRE) may allow non-invasive, and potentially early diagnosis of CP and PI. Currently, however, normative data with which to compare MR-PFT and MRE results in pediatric patients with suspected CP/PI is not available. Aims: The investigators propose to determine the normal range for secreted pancreatic fluid volume in response to secretin administration and determine the normal range for pancreatic parenchymal stiffness in a pediatric population that is not affected by pancreatic disease. To date, the investigators have validated their MRCP technique and have successfully performed both MR-PFT and MRE in CP patients; however normative data is essential for validation of our non-invasive technique.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Aug 17, 2016
Study start
Aug 10, 2016
Primary completion
Apr 6, 2017
Study completion
Apr 6, 2017
Results posted
Aug 7, 2020
Registry updated
Aug 7, 2020
Outcomes
What the study measures.
Primary outcomes
Total Secreted Fluid Volume as Measured by MR-PFT
Time frame · 35 minutes (20 min pre-secretin, 15 minutes post-secretin)
Participants underwent MR imaging prior to and following secretin administration. Pre-secretin imaging lasts approximately 20 minutes. Post-secretin images were acquired at 1 minute, 5 minutes and 15 minutes following completion of secretin injection. Pre-secretin enteric fluid volumes were subtracted from post-secretin enteric fluid volumes for each participant to determine volume secreted in response to secretin administration at each time point. A commercially available software package determines the area of fluid signal on the MR images. The fluid signal from the pre-secretin images is then subtracted from the each post-secretin image (1, 5 and 15 minutes images) to determine the amount of fluid produced by the introduction of secretin.
Secondary outcomes
Pancreatic Stiffness as Measured by Magnetic Resonance Elastography (MRE)
Time frame · Single time point, pre-secretin
Healthy controls underwent 3D MRE on a 1.5T scanner. Regions of interest for measurement of pancreatic stiffness were drawn by two blinded readers and statistical analysis were performed for comparisons between the 2 groups.
Volumetric Measurement of Pancreatic Parenchymal Volume
Time frame · Single time point, pre-secretin
Pancreatic parenchymal volume by manual segmentation (tracing) of pancreas contours on magnetic resonance imaging (MRI)
Eligibility
Who can take part.
- Minimum age
- 6 Years
- Maximum age
- 15 Years
- Sex
- ALL
- Healthy volunteers
- Yes
Inclusion Criteria: 1. Subjects between the ages of 6 and 15.9 years. 2. Subjects without a documented history of (or suggestive of) pancreatic disease Exclusion Criteria: 1. History of pancreatic disease, liver disease, intra-abdominal neoplasm, abdominal inflammatory process such as inflammatory bowel disease (IBD), or systemic illness that may affect pancreatic state (e.g. cystic fibrosis). 2. Subjects with surgical hardware/implanted devices making them ineligible for MRI (e.g. pacemaker or other implanted medical device not approved for MRI). 3. Subjects who require any form of sedation or general anesthesia for MRI. 4. Subjects unable to breath-hold for the required 15-20 second imaging sequence. 5. Subjects who are pregnant or less than 12 months post-partum.
Study locations
1 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Publications
Results and literature.
Related trials
More studies on Secretin.
A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects
Mayo Clinic · Exocrine Pancreatic Insufficiency · Chronic Pancreatitis
Phase 4
Recruiting
24
2026-07
Secretin in Ex-situ Liver Perfusion
Erasmus Medical Center · Liver Transplantation
Phase 1 / Phase 2
Enrolling by invitation
20
2026-06
Imaging Biomarkers of Pancreatic Function and Disease
Children's Hospital Medical Center, Cincinnati · Pancreatitis · Diabetes Mellitus
Phase 4
Enrolling by invitation
195
2026-03
Secretin in Refeeding
University of California, Los Angeles · Anorexia in Adolescence
Not applicable
Recruiting
10
2026-02
Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies
M.D. Anderson Cancer Center · Pancreatitis
Not applicable
Recruiting
2,345
2025-10
The Cancer of the Pancreas Screening-5 CAPS5)Study
Johns Hopkins University · Pancreas Cancer · Peutz-Jeghers Syndrome (PJS)
Phase 3
Recruiting
9,000
2025-10
The Effects of Bariatric Surgeries on Glucose Metabolism
The University of Texas Health Science Center at San Antonio · Post Bariatric Surgery · Gastric Bypass
Early Phase 1
Recruiting
200
2025-09
The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
Adenocyte, LLC · IPMN, Pancreatic · Pancreas Cancer
Not applicable
Enrolling by invitation
500
2025-03
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.